Skip to main content
Top
Published in: Indian Journal of Surgical Oncology 4/2015

01-12-2015 | ORIGINAL ARTICLE

Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Authors: Narendra Hulikal, Sivanath Reddy Gajjala, Teck Chand Kalawat, Radhika Kottu, Lakshmi Amancharla Yadagiri

Published in: Indian Journal of Surgical Oncology | Issue 4/2015

Login to get access

Abstract

In India up to 50 % of breast cancer patients still present as locally advanced breast cancer (LABC). The conventional methods of metastatic work up include physical examination, bone scan, chest & abdominal imaging, and biochemical tests. It is likely that the conventional staging underestimates the extent of initial spread and there is a need for more sophisticated staging procedure. The PET/CT can detect extra-axillary and occult distant metastases and also aid in predicting response to chemotherapy at an early point in time. To evaluate the utility of FDG PET/CT in initial staging and response assessment of patients with LABC receiving NACT. A prospective study of all biopsy confirmed female patients diagnosed with LABC receiving NACT from April 2013 to May 2014. The conventional work up included serum chemistry, CECT chest and abdomen and bone scan. A baseline whole body PET/CT was done in all patients. A repeat staging evaluation and a whole body PET/CT was done after 2/3rd cycle of NACT in non-responders and after 3/4 cycles in clinical responders. The histopathology report of the operative specimen was used to document the pathological response. The FDG PET/CT reported distant metastases in 11 of 38 patients, where as conventional imaging revealed metastases in only 6. Almost all the distant lesions detected by conventional imaging were detected with PET/CT, which showed additional sites of metastasis in 3 patients. In 2 patients, PET/CT detected osteolytic bone metastasis which were not detected by bone scan. In 5 patients PET CT detected N3 disease which were missed on conventional imaging. A total of 14 patients had second PET/CT done to assess the response to NACT and 11 patients underwent surgery. Two patients had complete pathological response. Of these 1 patient had complete metabolic and morphologic response and other had complete metabolic and partial morphologic response on second PET/CT scan. The 18 FDG PET/CT can detect more number of metastasis as well as additional sites of metastasis compared to conventional methods. The response assessment resulted in change of treatment regimen in 14 % of patients.
Literature
2.
go back to reference AJCC (American Joint Committee on Cancer) (2010) In: Edge SB, Byrd DR, Compton CC et al (eds) Cancer staging manual, 7th edn. Springer, New York, p 347CrossRef AJCC (American Joint Committee on Cancer) (2010) In: Edge SB, Byrd DR, Compton CC et al (eds) Cancer staging manual, 7th edn. Springer, New York, p 347CrossRef
3.
go back to reference Tham YL, Kramer R, Osborne CK (2010) Evaluation of patients for metastasis prior to primary therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, p 483 Tham YL, Kramer R, Osborne CK (2010) Evaluation of patients for metastasis prior to primary therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, p 483
4.
go back to reference Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N et al (2008) Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19:1249–1254CrossRefPubMed Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N et al (2008) Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19:1249–1254CrossRefPubMed
5.
go back to reference Al-Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J et al (2008) Prevalence of overt metastases in locally advanced breast cancer. Clin Oncol (R Coll Radiol) 20(5):340–344CrossRef Al-Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J et al (2008) Prevalence of overt metastases in locally advanced breast cancer. Clin Oncol (R Coll Radiol) 20(5):340–344CrossRef
6.
go back to reference Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K et al (2001) Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351–358CrossRefPubMed Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K et al (2001) Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351–358CrossRefPubMed
7.
go back to reference Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E et al (2008) Effect of (18) F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71:695–704CrossRefPubMed Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E et al (2008) Effect of (18) F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71:695–704CrossRefPubMed
8.
go back to reference Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751CrossRefPubMed Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751CrossRefPubMed
9.
go back to reference Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, Van Geldere D et al (2004) 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 22:1253–1259CrossRefPubMed Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, Van Geldere D et al (2004) 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 22:1253–1259CrossRefPubMed
10.
go back to reference Von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, German Breast Group et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30CrossRef Von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, German Breast Group et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30CrossRef
11.
go back to reference De Boer RH, Saini A, Johnston SR, O’Brien ME, Ellis PA, Verrill MW et al (2000) Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. Breast 9:149–155CrossRefPubMed De Boer RH, Saini A, Johnston SR, O’Brien ME, Ellis PA, Verrill MW et al (2000) Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. Breast 9:149–155CrossRefPubMed
12.
go back to reference Auclerc G, Borel C, Khayat D, Soubrane C (1992) Weil M [Primary chemotherapy in the treatment of breast cancer]. Ann Chir Plast Esthet 37:663–669PubMed Auclerc G, Borel C, Khayat D, Soubrane C (1992) Weil M [Primary chemotherapy in the treatment of breast cancer]. Ann Chir Plast Esthet 37:663–669PubMed
13.
go back to reference Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer 95:681–695CrossRefPubMed Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer 95:681–695CrossRefPubMed
14.
go back to reference Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224–4237PubMed Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224–4237PubMed
15.
go back to reference Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan cancer institute. J Clin Oncol 16:93–100PubMed Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan cancer institute. J Clin Oncol 16:93–100PubMed
16.
go back to reference Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578–2581PubMed Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578–2581PubMed
17.
go back to reference NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 3.2014. National Comprehensive Cancer Network. Available at http://bit.ly/jOuSUf. Accessed October 2, 2014. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 3.2014. National Comprehensive Cancer Network. Available at http://​bit.​ly/​jOuSUf. Accessed October 2, 2014.
18.
go back to reference Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C et al (2013) 18F FDG PET/CT in patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 54:5–11CrossRefPubMed Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C et al (2013) 18F FDG PET/CT in patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 54:5–11CrossRefPubMed
19.
go back to reference Wolfgang A (2009) Weber. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:963–995 Wolfgang A (2009) Weber. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:963–995
20.
go back to reference Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemotherapy using positron emission tomography-initial evaluation. J Clin Oncol 11:2101–2111PubMed Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemotherapy using positron emission tomography-initial evaluation. J Clin Oncol 11:2101–2111PubMed
21.
go back to reference Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D et al (2000) Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689–1695PubMed Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D et al (2000) Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689–1695PubMed
22.
go back to reference Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al (2000) Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676–1688PubMed Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al (2000) Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676–1688PubMed
23.
go back to reference Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372CrossRefPubMed Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372CrossRefPubMed
24.
go back to reference McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102:75–84CrossRefPubMed McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102:75–84CrossRefPubMed
25.
go back to reference Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol 27:535–541CrossRefPubMed Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol 27:535–541CrossRefPubMed
26.
go back to reference Dunnwald LK, Gralow JR, Ellis GK (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457CrossRefPubMedPubMedCentral Dunnwald LK, Gralow JR, Ellis GK (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457CrossRefPubMedPubMedCentral
27.
go back to reference Groheux D, Hindie E, Giacchetti S, Delord M, Hamy AS, Roquancourt AD et al (2012) Triple negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at high risk of early relapse. J Nucl Med 53:249–254CrossRefPubMed Groheux D, Hindie E, Giacchetti S, Delord M, Hamy AS, Roquancourt AD et al (2012) Triple negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at high risk of early relapse. J Nucl Med 53:249–254CrossRefPubMed
28.
go back to reference Skoura EV, Datseris IE (2007) PET imaging in breast cancer. Hosp Chronicles 2:12–18 Skoura EV, Datseris IE (2007) PET imaging in breast cancer. Hosp Chronicles 2:12–18
Metadata
Title
Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Authors
Narendra Hulikal
Sivanath Reddy Gajjala
Teck Chand Kalawat
Radhika Kottu
Lakshmi Amancharla Yadagiri
Publication date
01-12-2015
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 4/2015
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-015-0421-0

Other articles of this Issue 4/2015

Indian Journal of Surgical Oncology 4/2015 Go to the issue